Date: 2014-10-01
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.
Company: Genoscience Pharma (France)
Product: GNS396
Action
mechanism: GNS396 is a new druggable small molecule that shows potent anti-proliferation activity in the NCI-60 panel of human tumor cell lines, notably against acute myeloid leukemia cell lines. In preclinical studies, GNS396 has shown a reduction in the percentage of cancer stem cells in AML cell lines and has induced leukemia regression in chemotherapy resistant models (ALDH gene family activity used as a marker of CSCs). Furthermore, GNS396 has shown a synergic effect in combination with the AML standard of care (Cytarabine).
Disease: acute myeloid leukemia
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On October 1, 2014, Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, announced that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014. Two lead compounds have been selected: GNS396 to treat acute myeloid leukemia (AML) and GNS561 to treat Hepatocellular Carcinoma. In AML, by simultaneously targeting the tumorigenic (with GNS396) and non-tumorigenic populations (with GNS396 and Cytarabine), both leukemia cell heterogeneity and plasticity could be overcome. “GNS396 and its analogues offer great promise for AML treatment and the prevention of relapse, particularly if combined with chemotherapy,” said Antoine Beret, general manager at Genoscience. “This breakthrough affords a unique opportunity to explore a new route against cancer.” “The forthcoming EORTC-NCI-AACR Symposium presentation will demonstrate our deep knowledge of the role of cancer stem cells as the pivotal factor in leukemia progression and relapse,” said Professor Philippe Halfon, MD, Ph.D., president and founder, Genoscience. “We will showcase our growing pipeline of pre-clinical product candidates. The research data supports our future clinical development in Acute Myeloid Leukemia (AML). We will present evidence from our experiments with the cancer stem cell targeting agent GNS396 and explain how it reacts by inhibiting the autophagy pathways.”
